Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The Rehabilitation Enhancing Aging Through Connected Health Prehabilitation Trial.

Bean JF, Brown L, DeAngelis TR, Ellis T, Kumar VSS, Latham NK, Lawler D, Ni M, Perloff J.

Arch Phys Med Rehabil. 2019 May 29. pii: S0003-9993(19)30380-6. doi: 10.1016/j.apmr.2019.04.015. [Epub ahead of print]

PMID:
31152705
2.

MicroRNA-21 is Required for Hematopoietic Cell Viability After Radiation Exposure.

Puccetti MV, Adams CM, Dan TD, Palagani A, Simone BA, DeAngelis T, Eischen CM, Simone NL.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1165-1174. doi: 10.1016/j.ijrobp.2019.04.020. Epub 2019 Apr 27.

PMID:
31039423
3.

Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study.

Ellis TD, Cavanaugh JT, DeAngelis T, Hendron K, Thomas CA, Saint-Hilaire M, Pencina K, Latham NK.

Phys Ther. 2019 Feb 1;99(2):203-216. doi: 10.1093/ptj/pzy131.

PMID:
30715489
4.

Accuracy of Activity Trackers in Parkinson Disease: Should We Prescribe Them?

Wendel N, Macpherson CE, Webber K, Hendron K, DeAngelis T, Colon-Semenza C, Ellis T.

Phys Ther. 2018 Aug 1;98(8):705-714. doi: 10.1093/ptj/pzy054.

PMID:
29718452
5.

The rehabilitation enhancing aging through connected health (REACH) study: study protocol for a quasi-experimental clinical trial.

Ni M, Brown LG, Lawler D, Ellis TD, Deangelis T, Latham NK, Perloff J, Atlas SJ, Percac-Lima S, Bean JF.

BMC Geriatr. 2017 Sep 20;17(1):221. doi: 10.1186/s12877-017-0618-x.

6.

Teaching Evidence-Based Practice across Curricula-An Overview of a Professional Development Course for Occupational Therapy Educators.

Daly MM, DeAngelis TM.

Occup Ther Health Care. 2017 Jan;31(1):102-109. doi: 10.1080/07380577.2016.1227892. Epub 2016 Sep 30.

PMID:
27689791
7.

Highly Challenging Balance Program Reduces Fall Rate in Parkinson Disease.

Sparrow D, DeAngelis TR, Hendron K, Thomas CA, Saint-Hilaire M, Ellis T.

J Neurol Phys Ther. 2016 Jan;40(1):24-30. doi: 10.1097/NPT.0000000000000111.

8.

Diagnosis of multiple sclerosis.

Deangelis TM, Miller A.

Handb Clin Neurol. 2014;122:317-42. doi: 10.1016/B978-0-444-52001-2.00013-3. Review.

PMID:
24507524
9.

Clinical course in multiple sclerosis patients presenting with a history of progressive disease.

Pandey KS, Krieger SC, Farrell C, Hannigan C, DeAngelis T, Miller AE, Lublin FD.

Mult Scler Relat Disord. 2014 Jan;3(1):67-71. doi: 10.1016/j.msard.2013.05.004. Epub 2013 Jul 19.

PMID:
25877975
10.

Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.

Yoshida M, Selvan S, McCue PA, DeAngelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T.

Pigment Cell Melanoma Res. 2014 Mar;27(2):297-308. doi: 10.1111/pcmr.12206. Epub 2014 Jan 6.

PMID:
24354797
11.

The standardized patient encounter: a dynamic educational approach to enhance students' clinical healthcare skills.

Herge EA, Lorch A, Deangelis T, Vause-Earland T, Mollo K, Zapletal A.

J Allied Health. 2013 Winter;42(4):229-35.

PMID:
24326920
12.

Evidence-based practice in occupational therapy curricula.

DeAngelis TM, DiMarco TG, Toth-Cohen S.

Occup Ther Health Care. 2013 Oct;27(4):323-32. doi: 10.3109/07380577.2013.843115.

PMID:
24102588
13.

Feasibility of a virtual exercise coach to promote walking in community-dwelling persons with Parkinson disease.

Ellis T, Latham NK, DeAngelis TR, Thomas CA, Saint-Hilaire M, Bickmore TW.

Am J Phys Med Rehabil. 2013 Jun;92(6):472-81; quiz 482-5. doi: 10.1097/PHM.0b013e31828cd466.

14.

Barriers to exercise in people with Parkinson disease.

Ellis T, Boudreau JK, DeAngelis TR, Brown LE, Cavanaugh JT, Earhart GM, Ford MP, Foreman KB, Dibble LE.

Phys Ther. 2013 May;93(5):628-36. doi: 10.2522/ptj.20120279. Epub 2013 Jan 3.

15.

Growth of v-src-transformed cells in serum-free medium through the induction of growth factors.

Deangelis T, Quong A, Morrione A, Baserga R.

J Cell Physiol. 2013 Jul;228(7):1482-6. doi: 10.1002/jcp.24303.

16.

Clinical reasoning: a middle-aged woman with progressive symmetric weakness and a CSF pleocytosis.

Marks D, Jann A, DeAngelis T.

Neurology. 2012 Apr 3;78(14):e88-92. doi: 10.1212/WNL.0b013e31824e8f30. No abstract available.

PMID:
22474301
17.

Treating orthostatic hypotension in patients with Parkinson's disease and atypical Parkinsonism improves function.

Hohler AD, Amariei DE, Katz DI, DePiero TJ, Allen VB, Boyle S, Phenix HA, DeAngelis TA, Geibel CD, Smith KM, Saint-Hilaire M, Ellis T.

J Parkinsons Dis. 2012;2(3):235-40. doi: 10.3233/JPD-2012-012101.

PMID:
23938231
18.

The type 1 insulin-like growth factor receptor and resistance to DACH1.

DeAngelis T, Wu K, Pestell R, Baserga R.

Cell Cycle. 2011 Jun 15;10(12):1956-9. Epub 2011 Jun 15.

PMID:
21558809
19.

Multiple sclerosis as a model neurologic disease.

Lublin FD, DeAngelis TM.

Mt Sinai J Med. 2011 Mar-Apr;78(2):159-60. doi: 10.1002/msj.20238. No abstract available.

PMID:
21425261
20.

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.

Lünemann A, Tackenberg B, DeAngelis T, da Silva RB, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C.

Int Immunol. 2011 Feb;23(2):139-48. doi: 10.1093/intimm/dxq463. Epub 2011 Jan 6.

21.

Symptomatologic versus neuroimaging predictors of in-hospital survival after intracerebral haemorrhage.

Savadi-Oskouei D, Sadeghi-Bazargani H, Hashemilar M, DeAngelis T.

Pak J Biol Sci. 2010 May 1;13(9):443-7.

PMID:
20973398
22.

Patient management problem.

Deangelis TM.

Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):226-33. doi: 10.1212/01.CON.0000389954.27724.00. No abstract available.

PMID:
22810608
23.

Mutual interaction and reciprocal down-regulation between c-met and insulin receptor substrate-1.

DeAngelis T, Morrione A, Baserga R.

J Cell Physiol. 2010 Sep;224(3):658-63. doi: 10.1002/jcp.22164.

PMID:
20578241
24.

Outbreak of progressive inflammatory neuropathy following exposure to aerosolized porcine neural tissue.

Deangelis TM, Shen L.

Mt Sinai J Med. 2009 Oct;76(5):442-7. doi: 10.1002/msj.20132. Review.

PMID:
19787653
25.

Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway.

La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, Baserga R.

J Cell Physiol. 2009 Aug;220(2):485-91. doi: 10.1002/jcp.21796.

PMID:
19391107
26.

Regulation of insulin receptor substrate-1 expression levels by caveolin-1.

Chen J, Capozza F, Wu A, Deangelis T, Sun H, Lisanti M, Baserga R.

J Cell Physiol. 2008 Oct;217(1):281-9. doi: 10.1002/jcp.21498.

PMID:
18506777
27.

Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies.

DeAngelis T, Lublin F.

Mt Sinai J Med. 2008 Mar-Apr;75(2):157-67. doi: 10.1002/msj.20030. Review.

PMID:
18500719
28.

Multiple sclerosis: new treatment trials and emerging therapeutic targets.

DeAngelis T, Lublin F.

Curr Opin Neurol. 2008 Jun;21(3):261-71. doi: 10.1097/WCO.0b013e328300c70d. Review.

PMID:
18451708
29.

Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells.

Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R.

J Biol Chem. 2007 Nov 9;282(45):32582-90. Epub 2007 Sep 7.

30.

Single-fiber electromyography shows terminal axon dysfunction in Miller Fisher syndrome: a case report.

Lange DJ, DeAngelis T, Sivak MA.

Muscle Nerve. 2006 Aug;34(2):232-4.

PMID:
16583369
31.

Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling.

DeAngelis T, Chen J, Wu A, Prisco M, Baserga R.

Oncogene. 2006 Jan 5;25(1):32-42.

PMID:
16170362
32.

The GC factor regulates the expression of the insulin-like growth factor-I receptor.

Morrione A, DeAngelis T, Baserga R.

Cell Prolif. 1995 Dec;28(12):659-71.

PMID:
8634373
34.
35.
36.

Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts.

Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R.

Mol Cell Biol. 1994 Jun;14(6):3604-12.

37.

Clinton's climate change action plan.

DeAngelis T.

Environ Health Perspect. 1994 May;102(5):448-9. No abstract available.

38.

Mercury--gold minigrid optically transparent thin-layer electrode.

Meyer ML, DeAngelis TP, Heineman WR.

Anal Chem. 1977 Apr;49(4):602-6. No abstract available.

PMID:
848767
39.

Thin layer spectroelectrochemical study of vitamin B12 and related cobalamin compounds in aqueous media.

Kenyhercz TM, DeAngelis TP, Norris BJ, Heineman WR, Mark HB Jr.

J Am Chem Soc. 1976 Apr 28;98(9):2469-77. No abstract available.

PMID:
1262657

Supplemental Content

Loading ...
Support Center